Meet Novartis Management 2026

NOVARTIS



Speaker biographies

Corporate	Immunology	Cardiovascular, Renal & Metabolic
Vas Narasimhan	Fiona Marshall	Patrick Horber
Mukul Mehta	Angelika Jahreis	Ruchira Glaser
Ronny Gal	Richard Siegel	Shaun Coughlin
Steffen Lang	Christy Siegel	Dianne Auclair Rocha

Oncology	Neuroscience	AI
Shreeram Aradhye	Victor Bulto	Max Lawson
Andrea Myers	Nazem Atassi	Christian Diehl
Shiva Malek	Bob Baloh	
Reshema Kemps-Polanco	Renato Carvalho	



Vas Narasimhan

Chief Executive Officer

Vas Narasimhan is the CEO of Novartis, a global leader in biopharmaceuticals. Since becoming CEO in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company – one that delivers high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. He leads a company of around 75 000 associates that does business in approximately 120 countries and that reached more than 300 million patients with its medicines in 2025. Under his leadership, Novartis has experienced new heights of performance, marking some of the strongest years in the company's history.

Vas has focused his education and career on improving human health and on his personal purpose of inspiring a healthier world. During and after his medical studies, he worked on public health issues such as HIV/AIDS, malaria and tuberculosis in India, Africa and South America and continues to champion access and global health priorities today. Over his career, Vas has overseen the approval of over 35 novel medicines and vaccines.

Vas is an elected member of the US National Academy of Medicine, a member of the University of Chicago board of trustees, and a member of the board of fellows at Harvard Medical School. In 2026, he became a board member of Anthropic, as well as a member of the Council of Foreign Relations. Vas previously served as chair of the Pharmaceutical Research and Manufacturers of America and remains on its board of directors. In 2025, Vas was listed as one of the TIME100 Most Influential People in Health.

Originally from Pittsburgh, Pennsylvania, Vas lives in Basel, Switzerland, with his wife and two sons. A lifelong vegetarian, he is passionate about environmental and wildlife conservation – and is Chair of the African Parks Network, the largest conservation organization in Africa. He received his BA from the University of Chicago and his MD and MPP from Harvard University.



Mukul Mehta

Chief Financial Officer

Mukul Mehta was appointed Chief Financial Officer of Novartis on March 16, 2026, after more than 20 years working across financial functions and geographies at Novartis.

As CFO, Mukul shapes and executes the company's financial strategy, with a sharp focus on capital allocation, operational excellence and long-term value creation. He oversees enterprise-wide financial operations and leads investment across next-generation medicines, data and AI capabilities – advancing the company's ambition to reimagine medicine and deliver value for patients, shareholders and society.

Since joining Novartis in 2003, Mukul has served in wide-ranging and impactful roles across Commercial, Development, Business Services and Corporate Finance organizations. Prior to assuming the CFO role, he was Head of Business Planning & Analysis, Digital Finance and Tax, where he advanced integrated performance management and accelerated the adoption of data, automation, and digital tools across Finance. Before joining Novartis, Mukul worked in India's heavy engineering and banking sectors, gaining both industrial depth and financial experience in his early career.

As CFO, Mukul positions Finance as both a steward of capital and a strategic partner in reimagining medicine. He champions talent development, transparency, accountability, and data-driven insights to enable breakthrough innovation, optimize investment decisions and reinforce a culture of high performance.

Mukul holds an MBA from INSEAD, Fontainebleau, and a bachelor's degree in Electrical Engineering from PEC Chandigarh, India. He is married and has two children.



Ronny Gal

Chief Strategy & Growth Officer

In his role as Chief Strategy & Growth Officer, Ronny Gal is responsible for the end-to-end portfolio strategy of Novartis to support the company's long-term growth, including oversight of corporate strategy, research and development portfolio strategy and business development.

Ronny joined Novartis in July 2022, bringing over 20 years of experience in the life sciences industry spanning financial research and analytics, management consulting, and business development. As a thought leader in the healthcare sector, Ronny is recognized for his deep thematic research across therapeutic areas, technology platforms, and key industry topics such as US healthcare reform.

Prior to joining Novartis, Ronny was the senior analyst covering the US biopharmaceutical industry at Sanford Bernstein, a New York-based research and brokerage firm. Before joining Sanford Bernstein, Ronny started his career with the Boston Consulting Group, where he focused primarily on healthcare.

Ronny holds a doctorate in biochemistry from the Massachusetts Institute of Technology and a bachelor's degree in chemistry from Emory University, both in the US.



Steffen Lang

President, Operations

As President, Operations, Steffen Lang leads a team of 20 000 associates dedicated to manufacturing and supplying high-quality medicines to patients and providing operational support and high-quality services to the entire Novartis enterprise. Novartis Operations incorporates the company's manufacturing, quality, and supply organization, as well as data, digital & information technology, procurement & real estate, health, safety & environmental sustainability.

Prior to taking on this role, Steffen was Global Head of Novartis Technical Operations (NTO). Under his leadership, NTO underwent a transformation to become one of the leading manufacturing and supply organizations in the industry, providing agile, efficient support to the business, and reliably delivering life-changing medicines to patients around the world. During this time, the unit adapted its manufacturing capacity and capabilities to the changing needs of the Novartis strategy and product portfolio, maximizing the potential of its assets and expertise. As well as delivering technological innovation to enable the production of advanced therapeutic platforms, the unit collaborated with industry partners to support global demand for COVID-19 vaccines and therapies.

Steffen draws on a wealth of experience in the pharmaceutical industry, with a career that ranges from research through development to manufacturing and supply. He joined Novartis in 1994 as Head of Laboratory in Research and held positions of increasing responsibility before taking on his present role in 2022.



Fiona Marshall

President, Biomedical Research

Fiona Marshall is President of Novartis Biomedical Research, the company's innovation engine, where she leads approximately 5 300 scientists and other associates across nine research sites dedicated to the discovery of high-value medicines for patients.

Fiona collaborates with experts across the pipeline – from R&D to manufacturing and commercial development – to ensure Biomedical Research's technological and scientific breakthroughs translate into therapies that address the world's greatest disease burdens.

Prior to taking up her current role in November 2022, Fiona served as SVP and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co in the US). Prior to that, she was a founder and Chief Scientific Officer of Heptares Therapeutics, a UK-based biotechnology company focused on structure-based drug design. Earlier in her career, Fiona was director of molecular pharmacology at Millennium Pharmaceuticals and spent 10 years at GSK, holding senior positions in molecular pharmacology and neuroscience.

Fiona holds a bachelor's degree in biochemistry from University of Bath and a doctorate in neuroscience from the University of Cambridge, both in the UK. She was the recipient of the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship Award, the 2015 RSC Malcolm Campbell Award for Chemistry, and the Vane Medal from the British Pharmacological Society. She is also a fellow of the Royal Society and the Academy of Medical Sciences, and an honorary fellow of both the British Pharmacological Society and the Royal Society of Chemistry.



Angelika Jahreis

Global Head, Immunology Development Unit

Angelika Jahreis joined Novartis as Global Head of Immunology Development in 2020. She is a physician-scientist and board-certified dermatologist, with over two decades of experience in drug development. Prior to joining Novartis, she held roles of increasing responsibility at Gilead, Genentech, and Amgen. Angelika has a proven track record of developing drugs that have transformed the lives of adult and pediatric patients suffering from debilitating diseases.

Angelika is the steward of the immunology portfolio with assets across dermatology, allergy, rheumatology and gastroenterology that afflict more than 500 million people worldwide.

Angelika has worked closely with the FDA helping to establish the CARRA Consolidated Safety Registry (CoRe) for pediatric rheumatology and contributed to the assessment of the long-term benefit in osteoarthritis at the FDA/Arthritis Foundation Osteoarthritis Drug Development Workshop.

She serves as an independent director on the board of Agomab.



Richard Siegel

Global Head, Immunology, Biomedical Research

Richard Siegel is Global Head, Immunology at Novartis Biomedical Research, where he oversees a pre-clinical portfolio of immunomodulatory molecules being developed for immunology, as well as neuroscience, cardiovascular and renal indications. He has also had an active role in in-licensing and acquiring early-stage drug candidates from biotechnology companies, including NLRP3 and STING inhibitors and an anti-IL15 antibody.

Richard joined Novartis in 2018 as Head of Translational Medicine for Immunology and was appointed Immunology Research Disease Area Head in 2023. Before joining Novartis, Richard spent twenty years as a physician-scientist at the NIH intramural research program in Bethesda, Maryland. Most recently, he was Chief of the Autoimmunity Branch at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), conducting basic and translational research in cytokine biology focused on the TNF superfamily. From 2010 to 2018, he was also Clinical Director of NIAMS, overseeing its interventional and natural history studies. His work advanced the understanding of genetic immune dysregulation syndromes, including ALPS, TRAPS and CAPS, as well as the bone overgrowth condition melorheostosis.

Richard trained as a rheumatologist and immunologist at the University of Pennsylvania School of Medicine. He has authored more than 150 publications and has been elected to the American Society for Clinical Investigation and the Association of American Physicians.



Christy Siegel

Therapeutic Area Head, Immunology, US

Christy Siegel is Senior Vice President and Therapeutic Area Head, Immunology at Novartis US where she is making a significant impact for patients through growth of a multi-billion-dollar immunology portfolio.

For almost 20 years, Christy has held various roles within Novartis, most notably as General Manager, US Breast and Women's Cancers, Vice President and Head, US Solid Tumors franchise and Global and US Respiratory Franchise Head. Christy is a purpose-driven leader who brings deep and broad US commercial experience in complex specialty disease areas and across the research, development and commercialization continuum of pipeline planning, launch and growth maximization. She is known for building diverse, high-performing teams and championing a culture of inclusivity, authenticity, fun and genuine care for one another, centered in a patient-first mindset.

Christy holds a Doctor of Pharmacy degree from Rutgers University and resides in New Jersey with her husband and two children. She also volunteers as the executive sponsor of the Novartis CapABLE Employee Resource Group, an organization that empowers self-identified disabled individuals to reach their full potential and as a board member for her local Special Parents Association.



Patrick Horber

President, International

As President of Novartis International, Patrick Horber focuses on strengthening and growing the company's business in Europe, Asia, Africa, Australasia, Canada and Latin America.

Patrick has more than 20 years of experience in the biopharma sector. A proven leader with a deep understanding of the global pharmaceutical market, Patrick has significant experience enabling commercial performance on a global scale.

Patrick joined Novartis from AbbVie, where he served as SVP of AbbVie and President, Immunology. He was responsible for their Immunology Business Unit, leading the global strategy including global commercial development and the US execution. Prior to this role, as President, US Commercial Operations, Immunology, he successfully led the launch of two major immunology medicines in multiple indications in the US market and held a variety of leadership and general management positions in the US and in Europe.

Before joining AbbVie, Patrick held positions of increasing responsibility at Roche across diverse therapeutic areas including oncology, hematology, cardiometabolism, virology and anemia. He began his career in the healthcare practice of A.T. Kearney International.

Patrick holds a Doctor of Medicine from the University of Zurich in his native Switzerland. He speaks five languages.



Ruchira Glaser

Global Head, Cardiovascular, Renal & Metabolic Development Unit

Ruchira Glaser is Global Head of Cardiovascular, Renal and Metabolic Development at Novartis, where she oversees the development portfolio and leads the medicines development teams across the therapeutic area, driving advancements in innovative medicine and patient care.

With over 15 years of industry experience and 10 years of academic experience at the Hospital of the University of Pennsylvania, she has been instrumental in advancing clinical capabilities across global teams and driving internal and external innovation in the portfolio. Before this role, Ruchira was SVP, Global Head of Clinical Development at Novartis, where she led the clinical function, responsible for clinical development across all the core therapeutic areas of Novartis.

Before joining Novartis, Ruchira held senior roles in drug development at Moderna and GSK, including Therapeutic Area Head for Cardiovascular, Rare and Immunology at Moderna and Global Head of Clinical Sciences at GSK.

Prior to joining industry life sciences, she began her career as an interventional cardiologist and full-time attending faculty as Assistant Professor of Medicine in the Cardiovascular Division at the University of Pennsylvania, where she focused on specialized cardiovascular clinical research and interventional cardiovascular care.

Ruchira holds a Doctor of Medicine and a Bachelor of Science from Cornell University, as well as a Master's degree in Clinical Epidemiology and Biostatistics from the University of Pennsylvania. A Fellow of the American College of Cardiology, she has dedicated her career to advancing both cardiovascular and broader disease care, driving innovative medicines development, and improving patient outcomes worldwide.



Shaun Coughlin

Global Head, Cardiovascular & Metabolic, Biomedical Research

Shaun Coughlin is the Global Head, Cardiovascular and Metabolic at Novartis Biomedical Research. Since joining Novartis in 2017, he has led efforts in four critical areas of unmet medical need: atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, and obesity.

Shaun received his MD from Harvard Medical School and his PhD from the Massachusetts Institute of Technology. He completed his residency in internal medicine at Massachusetts General Hospital and his cardiology and postdoctoral fellowships at the University of California, San Francisco (UCSF), where he served as Distinguished Professor in Cardiovascular Biology and Medicine and Director of UCSF's Cardiovascular Research Institute until joining Novartis.

His academic laboratory uncovered the molecular mechanism by which the coagulation protease thrombin activates platelets and other cells and the roles this mechanism plays in vivo. This work provided a fundamental advance in the understanding of how normal and pathological blood clots form and led to the development of a novel antithrombotic.

Shaun was co-founder and board member of COR Therapeutics, board member of Millennium Pharmaceuticals, and held various other scientific advisory board roles.



Dianne Auclair Rocha

Therapeutic Area Head, Cardiovascular & Metabolic, US

Dianne Auclair Rocha is Senior Vice President and Therapeutic Area Head, Cardiovascular & Metabolic at Novartis US. In this role, she is responsible for the cross-functional strategy and commercialization of the current and future (10+ year) CVM pipeline, balancing near-term performance and execution while shaping mid-to-long range strategy for the US business.

With nearly 30 years of experience, Dianne has held progressively senior leadership roles across US and global functions, with deep expertise in CVM, neuroscience, and respiratory.

Recognized for her inspirational leadership, Dianne empowers teams to reimagine possibilities for patients and cultivate belief-driven cultures. In 2024, she was honored as a Healthcare Businesswomen's Association (HBA) Luminary for her dedication to developing future leaders and her impactful leadership for patients.

As she continues her commitment to patients and the healthcare community, Dianne serves on the Global Board of Directors for the HBA and the HBA Foundation and represents Novartis on the Healthcare Leadership Council.



Shreeram Aradhye

President, Development & Chief Medical Officer

As President, Development and Chief Medical Officer at Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines and overseeing medical activities across the company to bring meaningful new treatment options to patients.

Shreeram's organization leads the development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while generating the evidence needed to ensure our medicines can reach all patients who can benefit. As part of the Novartis strategy, Shreeram and his team play a central role in driving the company's mid- to long-term growth and delivering on its purpose to improve and extend people's lives, with a strong pipeline that includes investigational high-value treatments for cardiovascular, renal and immunological conditions, neurological disorders and various forms of cancer.

Shreeram began his current role at Novartis in May 2022, rejoining the company after spending several years at US biotechnology companies, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals. He first joined Novartis in 1999 and held a succession of leadership roles in the US, Switzerland, Germany and India, including Global Head of Medical Affairs for the Pharmaceuticals Business Unit and Development Head for the Neuroscience franchise.

Before joining the life sciences industry, Shreeram was an attending physician and assistant professor of medicine and a transplant nephrologist at the University of Pennsylvania. He completed his medical training at the All India Institute of Medical Sciences in 1989, after which he received additional specialty training in internal medicine and nephrology in the US.



Andrea Myers

Global Head, Oncology Development Unit a.i.

Andrea Myers is the ad interim Global Head, Oncology Development Unit at Novartis, where she oversees the oncology and hematology development portfolio and leads the development organization responsible for advancing innovative medicines across solid tumors and hematologic malignancies. She is responsible for guiding clinical strategy, portfolio governance, and the execution of development programs from early clinical development through registration and lifecycle management.

A board-certified medical oncologist, Andrea has built a career spanning academic medicine and the biopharmaceutical industry. Her work has focused on the development of innovative therapies across multiple tumor types and therapeutic platforms, including small molecules, biologics, cell therapies, radioligand therapies, and immuno-oncology approaches. Throughout her career, she has combined deep scientific expertise with a commitment to translating innovation into meaningful advances for patients.

Prior to her current role, Andrea held leadership positions within Novartis Oncology Development, including Clinical Development Head and Global Program Head. She has extensive international experience leading global development programs across North America, Europe, and Asia. Her work has contributed to the advancement of multiple oncology medicines and indications through close collaboration with investigators, regulators, and development partners worldwide.

Andrea earned her MD and PhD in Genetics from Stanford University School of Medicine and completed her training in Medical Oncology at the Dana Farber Cancer Institute before pursuing a career in drug development.



Shiva Malek

Global Head, Oncology, Biomedical Research

Shiva Malek is the Global Head, Oncology at Novartis Biomedical Research, spanning all aspects of oncology including solid tumors, hematology, immuno-oncology, cellular therapies and radioligand therapies. She received her PhD in Biochemistry from UCSD studying structure and function of NF-KB/IKB complexes. Shiva has a long-standing track record of oncology research and drug discovery having worked on two FDA approved drugs, vemurafenib and cobimetinib.

Shiva started her career in drug discovery at Vertex Pharmaceuticals and moved to Exelixis leading multiple oncology drug discovery programs. She has spent over 15 years at Genentech taking on roles of increasing responsibility, initially leading the oncology small molecule drug discovery programs and later serving as VP of Discovery Oncology. In this capacity, Shiva served on the Genentech Oncology Leadership Team and the Genentech Research Review Committee. She oversaw a broad portfolio of oncology programs spanning early-stage research to late-stage clinical programs.

Shiva is a world leading expert in RAS/MAPK biology having discovered that BRAF-V600E inhibitors induce paradoxical activation of MAPK signaling in BRAF WT and KRAS mutant tumors. Shiva received the 2025 AACR Award for Outstanding Achievement in Chemistry in Cancer Research, for her groundbreaking scientific contributions in cancer research and therapeutic innovation. Shiva holds numerous leadership roles including Adjunct Professor in the Department of Biochemistry and Biophysics at UCSF School of Medicine, Editorial Committee Member for Annual Reviews of Cancer Biology, Board Member for Cancer Molecular Therapeutics Research Association, and Chair of AACR Women in Cancer Research (2024-2025).



Reshema Kemps-Polanco

Chief Commercial Officer, US

Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, leading the commercialization of the company's portfolio across its key therapeutic areas.

With 25 years of healthcare industry experience, Reshema has led large commercial organizations and growth strategies across multiple therapeutic areas, notably in both oncology and cardiovascular. Prior to rejoining Novartis in 2021 as EVP and US Head Novartis Oncology, Reshema served as President of Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico. Before joining Johnson & Johnson, Reshema spent 15 years at Novartis where she led multiple commercial teams across oncology and specialty business units.

Reshema serves on the Board of Directors of Charles River Laboratories International and is a member of the CEO Roundtable on Cancer and the Rutgers Cancer Institute Leadership Council. She was named as the HBA 2025 Woman of the Year and a CNBC Changemaker in 2026.



Victor Bulto

President, US

As President of Novartis US, Victor Bulto is pursuing a bold strategy to reimagine medicine and deliver on the company's responsibility to unlock the potential for helping patients in the world's largest healthcare market.

Victor has been with Novartis for over 20 years and has broad, multi-national experience in the healthcare industry. Prior to this role, he served as President, Novartis Pharmaceuticals Corporation, leading the US pharmaceutical business. With a strong track record as a people-first leader he has also focused on creating a culture where each individual can show up every day as their authentic self to best serve the interest of people living with disease.

Victor is driven by the pressing need to translate medicines to outcomes for broad patient populations and transform the patient experience to help mitigate the challenges people living with disease face in getting diagnosed, obtaining medicine, and staying on treatment within the complex US healthcare system.



Nazem Atassi

Global Head, Neuroscience & Gene Therapies Development Unit

Nazem Atassi is a physician-scientist with over 15 years of experience in clinical drug development across academia and the pharmaceutical industry. As the Development Unit Head of Neuroscience & Gene Therapies at Novartis, he leads an inspiring group of talented drug developers who share his passion for delivering transformative treatments to patients with the highest unmet medical needs.

Nazem started his career designing and running multi-center clinical trials at the Neurological Clinical Research Institute, an academic CRO within Mass General Hospital. He worked part-time at Biogen and Pfizer before joining Sanofi as Head of Early Neuro-Development in 2019, then Head of Late Neuro-Development in 2025. He brings extensive experience in early and late clinical drug development and regulatory interactions and has a substantial research portfolio encompassing over 100 original research articles published in high-tier medical journals.

A neurologist by training, Nazem completed his residency in neurology at Boston Medical Center, followed by a fellowship in neuromuscular disorders at MGH. He holds a Master of Medical Sciences from Harvard Medical School and an Executive Master of Business Administration from the Massachusetts Institute of Technology.



Bob Baloh

Global Head, Neuroscience, Biomedical Research

Bob Baloh is Global Head, Neuroscience at Novartis Biomedical Research, where he leads efforts to advance scientific discovery and therapeutic innovation in neurological diseases.

Bob received his MD-PhD degree from Washington University and completed his neurology residency at Harvard's MGH/Brigham hospitals in Boston. He returned to Washington University for a fellowship in neuromuscular diseases and then joined as junior faculty to develop research programs focused on understanding the molecular mechanisms of neurologic diseases using insights from human genetics.

In 2011, Bob moved to Cedars-Sinai Medical Center in Los Angeles where he headed the Division of Neuromuscular Medicine, the Center for Neural Science and Medicine, was Vice Chair of Neurology research, and a Professor in Neurology at UCLA and Cedars-Sinai. There he developed programs in neuromuscular diseases with emphasis on ALS/frontotemporal dementia, Charcot-Marie-Tooth disease, and muscular dystrophies with a focus on multidisciplinary patient care and clinical research. He ran a successful basic laboratory research program studying molecular and cellular mechanisms underlying neurodegenerative disease.

Before joining Novartis in 2021, Bob was Vice President and Head of Research in Neuroscience and Rare Diseases at Roche Pharmaceuticals in Basel.



Renato Carvalho

Chief Commercial Officer, International a.i.

Renato Carvalho is the ad interim Chief Commercial Officer, International, leading the Commercial Launch Strategy team. The CLS team is responsible for developing and implementing strategies for new product launches, and for expanding patient impact on established brands by optimizing commercial strategies and strengthening execution.

Renato has 25 years of diverse experience in country, regional and global leadership roles spanning pharmaceuticals, consumer healthcare, medical devices, diagnostics and digital health. Prior to his current roles he was President of Novartis Brazil, and previously CEO of Philips Brazil and COO of Philips Latin America.

He brings particular depth in Latin America, one of Novartis' fastest-growing regions and has served on the boards of industry associations and health-technology ventures in the region, including as Chairman of ABIMED and Vice Chairman of Interfarma.

Renato holds a degree in Production Engineering from the Universidade Federal de Itajubá and an Executive MBA from the University of São Paulo. He speaks English, Portuguese and Spanish.



Max Lawson

Head, Process Innovation

Max Lawson leads AI and Process Innovation for Development at Novartis, where he is responsible for shaping and delivering AI at scale – from strategy and partnerships to adoption, governance, and measurable impact. An engineer by training with an MBA, he is drawn to complex systems and to redesigning how work gets done, not just optimizing existing tools.

Max has spent more than a decade at Novartis in roles spanning data, AI, automation, digital health, and enterprise transformation. Prior to his current position, he served as Head of Data, AI, and Automation in Global Drug Development, where he built and scaled a multi-year portfolio focused on data governance, end-to-end process automation, and applied AI in clinical development. He is recognized for building high-performing teams, connecting strategy to execution, and driving adoption of new ways of working across complex global organizations.

He holds an MBA from Boston University and a Bachelor's degree in Mechanical Engineering from Virginia Tech.



Christian Diehl

Chief Data & Digital Officer, Biomedical Research

Christian Diehl serves as Chief Data & Digital Officer at Novartis Biomedical Research and is a member of the BR leadership team. In his role he oversees the Data & Digital function and serves as the Chair of the Computational Science Council representing the embedded data science teams of BR. His organization is responsible for all scientific data flows & architecture, scientific software applications, software engineering and lab IT technology for BR.

Through various AI flagship initiatives such as TargetID, AI for Chemistry and Biologics, Predictive Safety, Translational and other AI and digital projects his teams drive AI enablement across our research processes in collaboration with the respective functions and disease areas to ensure BR becomes a fully AI enabled research organization. He also serves on the board of directors of Novartis Germany.

Christian joined Novartis in 2012 in Sandoz' Biosimilars and Oncology Unit first leading strategic planning & special projects before serving as the regional head of the Asia-Pacific region for the unit. As of 2016 he has worked for Novartis Pharma, leading the development transformation, co-leading both the Alcon and Sandoz corporate spin-offs, leading the enterprise-wide Transformation for Growth Program as well as devising and building the data42 platform. He started his career at Unilever, worked for several years at McKinsey & Company and is also a commissioned reserve officer of the German Navy. He holds a Master of Business Engineering from the Karlsruhe Institute of Technology, Germany, an MBA from INSEAD and a Diploma of Advanced Studies in Pharmaceutical Medicine from the European Center of Pharmaceutical Medicine at the University of Basel, Switzerland.


NOVARTIS